Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8228867 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 6 Pages |
Abstract
In this secondary analysis of the TAX 324 trial, TPF IC remains superior to PF IC after controlling for radiotherapy delivery time. Even with optimal IC and concurrent chemotherapy, a non-prolonged RTT is a crucial determinant of treatment success. Appropriate delivery of radiotherapy after IC remains essential for optimizing OS in LAHNC.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
David J. M.D., M.P.H., Marshall R. M.D., Roy B. M.D., Ph.D., Nicholas J. M.D., Ph.D., Robert I. M.D., Edward J. Ph.D., Phillip M. M.D., F.A.C.R.,